Spectinomycin (hydrochloride hydrate)
Spectinomycin (hydrochloride hydrate; CAS 22189-32-8) is an aminocyclitol antibiotic derived from Streptomyces spectabilis, targeting bacterial protein synthesis by interacting specifically with the 30S ribosomal subunit. Binding near helix 34 of the 16S rRNA, spectinomycin inhibits protein translation by preventing elongation factor G-mediated translocation of peptidyl-tRNA from the ribosomal A-site to the P-site. Resistance mutations to spectinomycin align closely with those conferring streptomycin resistance, confirming the 30S subunit as its primary target. It is applied in biomedical research to study ribosomal function, antibiotic binding dynamics, and bacterial resistance mechanisms.
| Storage | Store at -20°C |
| M.Wt | 495.4 |
| Cas No. | 22189-32-8 |
| Formula | C14H24N2O7·2HCl [5H2O] |
| Solubility | ≥49.5 mg/mL in H2O; ≥3.61 mg/mL in EtOH with gentle warming and ultrasonic; ≥92 mg/mL in DMSO |
| Chemical Name | (5aR,9aR,10aS)-decahydro-4aR,7S,9S-trihydroxy-2R-methyl-6S,8R-bis(methylamino)-4H-pyrano[3-b][1,4]benzodioxin-4-one, dihydrochloride pentahydrate |
| SDF | Download SDF |
| Canonical SMILES | [H][C@@]12[C@@](C(C[C@@H](C)O2)=O)(O)O[C@]3([H])[C@@H](NC)[C@@H](O)[C@@H](NC)[C@H](O)[C@@]3([H])O1.Cl.Cl.O.O.O.O.O |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
| Cell experiment:[1] | |
|
Cell lines |
Escherichia coli B |
|
Reaction Conditions |
50 μg/mL spectinomycin |
|
Applications |
When added to an exponentially growing culture, spectinomycin (50 μg/mL) rapidly and reversibly inhibited growth of Escherichia coli B. Amino acid incorporation was slowed immediately but RNA synthesis continued. |
| Animal experiment:[2] | |
|
Animal models |
Male Sprague-Dawley rats, 200 ~ 225 g |
|
Dosage form |
10 mg/kg Administered intravenously (IV) |
|
Applications |
Following IV administration, approximately 55% of the drug was excreted into the urine in unchanged form. Spectinomycin at the dose of 10 mg/kg showed a peak plasma concentration of 37.8 μg/mL and a systemic exposure (area-under the curve AUC0-∞) of 15.7 μg h/mL. |
|
Note |
The technical data provided above is for reference only. |
|
References: 1. Davies J, Anderson P, Davis BD. Inhibition of protein synthesis by spectinomycin. Science, 1965, 149(3688): 1096-1098. 2. Madhura DB, Lee R, Meibohm B. Pharmacokinetic profile of spectinomycin in rats. Pharmazie, 2013, 68(8): 675-676. |
|
Quality Control & MSDS
- View current batch:
Chemical structure
